The company's innovative approach involves injecting HIF2ai inhibitors into the muscle, with potential for topical and oral methods. This treatment addresses the limited options currently available for muscle strain, damage, and dystrophy, such as physical therapy, surgery, and short-term drugs. By preventing the formation of scar tissue, HAWA's HIF2Ai technology accelerates initial recovery and reduces the risk of recurrent injuries. This has the potential to significantly improve the quality of life for individuals suffering from moderate to severe muscle strains, who often experience immense pain and extended periods of work absence.